bs-15197R [Primary Antibody]
C5 Polyclonal Antibody
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: C5

Immunogen Range: 951-1100/1676


Clonality: Polyclonal

Isotype: IgG

Entrez Gene: 727

Swiss Prot: P01031

Source: KLH conjugated synthetic peptide derived from human C5

Purification: Purified by Protein A.

Storage Buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Background:

The complement component proteins: C2, C3, C4 and C5 are potent anaphyl-atoxins that are released during complement activation. Binding of these proteins to their respective G protein-coupled receptors, C3aR, C1R and C5aR, induces proinflammatory events, such as cellular degranulation, smooth muscle contraction, arachidonic acid metabolism, cytokine release, leukocyte activation and cellular chemotaxis. Activation of the complement system leads to the formation of C5b-9 terminal complex, and while C5b-9 can promote cell lysis, the sublytic assembly of C5b-9 on plasma membranes causes an opposite result and induces cell cycle activation and survival. C5b-9 can rescue oligodendrocytes from FAS-mediated apoptosis by regulating caspase-8 processing via PI 3-K signaling. C5b-9 may play a pro-inflammatory role in the acute phase of multiple sclerosis, but may also be neuroprotective during the chronic phase of the disease. Complement C5 precursor contains C5a anaphylatoxin. C3a and C5a secretion correlates with pathophysiological phenotypes such as asthma and bacterial meningitis.

Size: 100ul

Concentration: 1ug/ul

Applications: WB(1:300-5000)
ELISA(1:500-1000)
IHC-P(1:200-400)

Predicted Molecular Weight: 104/112


Cross Reactive Species: Human

Predicted Cross Reactive Species: Mouse
Rat

For research use only. Not intended for diagnostic or therapeutic use.

VALIDATION IMAGES

Lane 1: Human A549 cell lysates; Lane 2: Human Hela cell lysates probed with C5 Polyclonal Antibody, Unconjugated (bs-15197R) at 1:1000 dilution and 4˚C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.